HomeResearch Reports

Emcure Pharmaceuticals Shares

Emcure Pharmaceuticals company logo

Emcure Pharmaceuticals

DMAT

PUBLIC LIMITED

Price Chart

1W
1M
1Y
MAX

High

-

Low

-

Return

-

Buy Sell Emcure Pharmaceuticals

As of August 08, 2026, Emcure Pharmaceuticals Ltd, Listed Shares are trading at ₹1,967.00 per share.

ISIN

info icon

INE168P01015

Face Value

info icon

10

Total Shares

info icon

18,11,52,116

Market Cap

info icon

35,632.62 Cr

Profit After Tax

info icon

527.58 Cr

Total Revenue

info icon

6,671.57 Cr

P/E

info icon

71.42

P/B

info icon

12.35

Sector

info icon

Health Care

Sub-sector

info icon

Pharmaceuticals

Category

info icon

Listed

Cashflow - Operations

info icon

1,097.24 Cr

About Emcure Pharmaceuticals

Company Overview:

  • Emcure was incorporated by Mr. Satish Mehta in 1981; the company commenced operations in 1983 in Pune, Maharashtra.
  • Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
  • The group has 13 manufacturing facilities across India and 5 R&D center's. The manufacturing facilities can manufacture pharmaceutical and biopharmaceutical products across a wide range of dosage forms, including oral solids, oral liquids, injectables, including liposomal and lyophilized injectables, biotherapeutics and complex APIs.
  • Emcure is an R&D driven company and their core strength lies in their ability to research, develop and manufacture in house specialty pharmaceutical products for high-growth therapeutic areas, for which there is limited competition and high barriers to entry.
  • Target market across 70 countries, with a strong presence in INDIA, Europe and Canada.
  • Emcure Pharmaceuticals sales in India contributed 53.16% of their total revenue from operation and rest 46.84% outside of India in FY2023.
  • As of September 30, 2023, Emcure had been granted 201 patents and had 33 pending patent applications in several countries, and had submitted 102 DMFs for APIs with the USFDA.

Want to See a Detailed Investment Analysis?

Explore in-depth financial analysis, performance metrics, and key disclosures.

Emcure Pharmaceuticals

₹ 1,967

cartIcon